Login / Signup

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.

Paula Jimenez-FonsecaVictoria FoySophie RabyAlberto Carmona-BayonasLola Macía-RivasVirginia ArrazubiDiego Cacho LavinRaquel Hernandez San GilAna CustodioJuana María CanoAna Fernández MontesOriol MirallasIsmael Macias DeclaraRosario Vidal TocinoLaura VisaMaría Luisa LimónPaola PimentelNieves Martínez-LagoTamara SauriMarta Martín RichardMonserrat MangasMireia Gil RagaAitana CalvoPablo RegueraMónica GranjaAlfonso Martín CarniceroCarolina Hernández PérezPaula CerdáLucía Gomez GonzalezFrancisco Garcia NavalonVilma Pacheo-BarciaDavid Gutierrez AbadMaribel Ruiz MartínJamie WeaverWasat MansoorJavier Gallego
Published in: Therapeutic advances in medical oncology (2023)
The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.
Keyphrases
  • epidermal growth factor receptor
  • locally advanced
  • free survival
  • metastatic breast cancer
  • squamous cell carcinoma
  • stem cells
  • tyrosine kinase
  • bone marrow
  • chemotherapy induced
  • replacement therapy